This study systematically summarizes the translational potential of CAR T cells in non-cancerous conditions such as autoimmunity, infections, and fibrosis, providing a critical mechanistic framework and clinical roadmap for designing precise immunotherapies targeting pathological cell populations. It offers direct guidance for treatment strategies in systemic lupus erythematosus and chronic viral infections.
Literature Overview
This article, 'CAR T cell therapy beyond cancer: current status, challenges and future prospects,' published in Signal Transduction and Targeted Therapy, systematically explores the expansion of chimeric antigen receptor (CAR) T cell therapy from oncology into chronic non-malignant diseases. The study reviews the application of CAR-T in various persistent, pathologically driven conditions, including viral infections, autoimmune disorders, fibrosis, hemophilia, transplant rejection, and cellular senescence. The authors emphasize that the core principle of CAR-T therapy—precise antigen recognition coupled with long-lasting effector functions—can be redirected to eliminate or reprogram long-lived pathogenic cells, thereby restoring tissue homeostasis and resetting the immune system. This approach overcomes the limitations of traditional therapies that merely suppress symptoms, offering a new pathway toward curative interventions.Background Knowledge
Currently, autoimmune diseases such as systemic lupus erythematosus (SLE) and multiple sclerosis still rely on long-term immunosuppressive treatments. These therapies not only increase the risks of infection and malignancy but also fail to eliminate long-lived plasma cells and autoreactive B cells, leading to disease relapse. Similarly, chronic viral infections like HIV and HBV can be controlled with antiviral drugs, but latent viral reservoirs persist and rebound upon treatment cessation. The shared biological challenge in these diseases is the prolonged survival and immune evasion of pathogenic cells, which are difficult for conventional drugs to eradicate. The introduction of CAR T cell therapy leverages its 'living drug' properties—capacity for expansion, persistence, and memory formation—to specifically eliminate cells expressing target antigens. The key innovation lies in redefining CAR-T from a 'tumor cell killer' into a platform for 'immune ecosystem reprogramming,' enabling precise elimination of pathogenic cell populations by targeting markers such as CD19, BCMA, FAP, and uPAR. This strategy is not only applicable to B cell-mediated diseases but can also extend to fibrotic fibroblasts, senescent cells, and alloreactive T cells, demonstrating broad adaptability.
Research Methods and Experiments
The authors conducted a comprehensive analysis of multiple preclinical and early clinical studies involving the use of CAR-T cells in HIV, EBV, systemic lupus erythematosus, systemic sclerosis, and myocarditis. The research relied on various animal models, including humanized NSG mice for HIV studies, NOD/SCID xenograft models for EBV-related lymphoma, and multiple genetically engineered mouse models for autoimmune and fibrosis research. Key experiments included: treating refractory SLE patients with CD19-CAR-T cells, resulting in complete B cell depletion, reduced autoantibody levels, and drug-free remission; in HBV infection models, CAR-T cells targeting surface antigens on hepatocytes effectively cleared infected cells; in fibrosis models, FAP-CAR-T cells reduced cardiac and pulmonary fibrosis. These results collectively support the feasibility and durable efficacy of CAR-T therapy in non-oncological settings.Key Conclusions and Perspectives
Research Significance and Prospects
This study advances a paradigm shift in CAR-T therapy—from cancer treatment to chronic disease management. At the drug development level, it supports the creation of CAR-T products targeting non-cancer antigens, such as those aimed at eliminating anti-FVIII antibodies in hemophilia. In clinical monitoring, new efficacy assessment criteria are needed—such as immune reconstitution dynamics and changes in autoantibody titers—rather than relying solely on tumor shrinkage. In disease modeling, combining humanized mice with CAR-T therapy can simulate human immune resetting, accelerating therapy optimization.
Conclusion
This study systematically demonstrates the broad potential of CAR T cell therapy beyond oncology, elevating it from a cytotoxic tool to a platform for immune system 'reprogramming.' By targeting markers such as CD19, BCMA, and FAP, CAR-T cells can eliminate pathogenic B cells, plasma cells, fibrotic fibroblasts, and senescent cells, enabling tissue repair and restoration of immune homeostasis. In the laboratory, this strategy depends on precise animal models and genetic engineering tools, such as humanized mice and conditional expression systems. In clinical translation, existing cases in SLE and HIV treatment have proven its feasibility, although challenges remain regarding safety, antigen escape, and long-term immune reconstitution. In the future, integrating regulatable CARs, logic-gated circuits, and in vivo programming technologies may enable safer and more precise interventions for chronic diseases. This study establishes a new cornerstone for treating autoimmune disorders, chronic infections, and age-related conditions, positioning CAR-T as a core technology in next-generation chronic disease management.
